Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned fundraising through debt or equity in the transcript. The company has reported a reduction in interest burden due to repayment of a substantial part of its NCD and other loans post their QIP issue. Interest cost has declined 55% year-on-year during the quarter, and they are working on further measures to reduce interest burden. Capex for the nine months ending December 2024 was INR173 crores mainly for the albumin facility, indicating ongoing investment funded through internal or existing resources. The management did not provide any guida

Any current/future capex/capital investment/strategic investment?

Capex for nine months ending December 2024 was INR 173 crores, mainly for the albumin facility under development (Page 8). The albumin facility, for recombinant human albumin (a New Biological Entity), is in material generation phase with Phase III human studies planned to start in Q1 FY '26 (Page 7). The company is focusing on building capacity and capabilities in biologics and CDMO segments, including fermentation-based CDMO projects and ADC (antibody-drug conjugate) development (Pages 7, 18). Continuous investment in diverse verticals such as APIs, formulations, peptides, polymers, biologic

Future growth expectations in sales/revenue/volumes?

Biologics segment is gaining good traction with multiple licensing opportunities and CDMO contracts contributing to future revenue growth. (Page 13, 19) Top 3 revenue generators next financial year expected to be Nilotinib, Axitinib, and CDMO products. (Page 18) Oncology API business expected to improve from Q1 FY'26, with ramp-up in supplies to partners like Intas. (Page 14, 15) Non-oncology business set for growth by replacing old products with high-margin molecules like UDCA and NorUDCA from Q1 FY'26. (Page 14) Licensing income from multiple pipeline molecules will continue as a major reven

Future growth expectations in earnings/operating earnings/profits/EPS?

EBITDA margins of 26%-27% are sustainable, with opportunities to improve further (Page 16). Profit after tax for 9 months doubled compared to the previous financial year, showing strong profit growth (Page 8). Licensing income from multiple pipeline products and CDMO contracts is expected to continue as a key revenue and profitability driver (Pages 16-17). Growth driven by key molecules like Nilotinib, Axitinib, and CDMO products, with formulation sales expected to increase as licensed products commercialize (Pages 8, 15, 18). Biologics business showing good traction with expected sizable reve

Current/ Expected Orderbook/ Pending Orders?

Shilpa Medicare has a very strong order book in formulations across Europe, US, and other global markets, supported by multiple product registrations and approvals from previous years. The company has ongoing supply commitments, including a launch order for 5 million tablets under the Unicycive partnership for a CDMO project, with formulation supplies planned for Q1/Q2 FY '26. For the specialty polymer segment, Shilpa received a ~$4 million single purchase order from an Indian partner, with supplies expected to complete in Q1 FY '26, followed by anticipated repetitive orders. The company is ac

IN US

Sale is live|00:00:00left today

Shilpa Medicare LtdQ4 FY26Pharmaceuticals & Biotechnology

Shilpa Medicare Ltd Q4 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹591P/E: 52.9Market Cap: ₹9.4K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Biologics segment is gaining good traction with multiple licensing opportunities and CDMO contracts contributing to future revenue growth. (Page 13, 19)
→Top 3 revenue generators next financial year expected to be Nilotinib, Axitinib, and CDMO products. (Page 18)
→Oncology API business expected to improve from Q1 FY'26, with ramp-up in supplies to partners like Intas. (Page 14, 15)
→Non-oncology business set for growth by replacing old products with high-margin molecules like UDCA and NorUDCA from Q1 FY'26. (Page 14)
→Licensing income from multiple pipeline molecules will continue as a major revenue driver alongside formulation sales. (Page 9, 16, 17)
→Europe and Rest of World markets hold significant growth opportunities especially with new API approvals and higher formulation sales driven by recent product launches like Nilotinib and Axitinib. (Page 11)
→CDMO business presents a good gross margin opportunity with multiple molecules in the pipeline. (Page 17)

Margin guidance

Category 3

→EBITDA margins of 26%-27% are sustainable, with opportunities to improve further (Page 16).
→Profit after tax for 9 months doubled compared to the previous financial year, showing strong profit growth (Page 8).
→Licensing income from multiple pipeline products and CDMO contracts is expected to continue as a key revenue and profitability driver (Pages 16-17).
→Growth driven by key molecules like Nilotinib, Axitinib, and CDMO products, with formulation sales expected to increase as licensed products commercialize (Pages 8, 15, 18).
→Biologics business showing good traction with expected sizable revenues and potential for INR300 crore scale by FY '27 (Pages 12-13).
→Margin improvement expected due to better operating leverage, asset utilization, and improved business mix (Page 8).
→Tax rate expected to normalize near 35% in FY '26, improving net earnings (Page 15).
→Revenue growth expected in non-oncology with shift to higher margin products like UDCA and NorUDCA from FY '26 onwards (Page 15).

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any current or planned fundraising through debt or equity in the transcript.
→The company has reported a reduction in interest burden due to repayment of a substantial part of its NCD and other loans post their QIP issue.
→Interest cost has declined 55% year-on-year during the quarter, and they are working on further measures to reduce interest burden.
→Capex for the nine months ending December 2024 was INR173 crores mainly for the albumin facility, indicating ongoing investment funded through internal or existing resources.
→The management did not provide any guidance on future fundraising activities during the call.

Order book

→Shilpa Medicare has a very strong order book in formulations across Europe, US, and other global markets, supported by multiple product registrations and approvals from previous years.
→The company has ongoing supply commitments, including a launch order for 5 million tablets under the Unicycive partnership for a CDMO project, with formulation supplies planned for Q1/Q2 FY '26.
→For the specialty polymer segment, Shilpa received a ~$4 million single purchase order from an Indian partner, with supplies expected to complete in Q1 FY '26, followed by anticipated repetitive orders.
→The company is actively building its CDMO pipeline with several molecules in advanced stages and expects new launches and milestones to contribute to future order flows.
→Overall, Shilpa is poised for growth with multiple assets nearing commercialization and a robust pipeline fueling continuous ordering.

Capex plans

Yes

→Capex for nine months ending December 2024 was INR 173 crores, mainly for the albumin facility under development (Page 8).
→The albumin facility, for recombinant human albumin (a New Biological Entity), is in material generation phase with Phase III human studies planned to start in Q1 FY '26 (Page 7).
→The company is focusing on building capacity and capabilities in biologics and CDMO segments, including fermentation-based CDMO projects and ADC (antibody-drug conjugate) development (Pages 7, 18).
→Continuous investment in diverse verticals such as APIs, formulations, peptides, polymers, biologics, and fermentation to leverage multi-offerings at customers (Page 18).
→Ongoing efforts to improve asset utilization and operating leverage to support margin expansion (Page 8).

How does Shilpa Medicare Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Shilpa Medicare Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Shilpa Medicare Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio